Shares of Medicure Inc. (CVE:MPH – Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as C$1.47 and last traded at C$1.47, with a volume of 8512 shares traded. The stock had previously closed at C$1.30.
Medicure Price Performance
The company has a debt-to-equity ratio of 6.02, a quick ratio of 1.28 and a current ratio of 0.97. The firm has a market cap of C$19.83 million, a price-to-earnings ratio of -2.64 and a beta of 0.44. The stock’s 50 day simple moving average is C$1.24 and its 200-day simple moving average is C$1.16.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Further Reading
- Five stocks we like better than Medicure
- Could Falling Yields Make REIT Stocks Worth a Second Look?
- CrowdStrike’s “Mythos Moment” Tests the Bigger AI Security Trade
- 3 Stocks Facing New Pressure From Section 338 Tariffs on Canadian Goods
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
